News Alar Pharmaceuticals Inc.

Equities

6785

TW0006785009

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
270 ^TWD	0.00%		+9.76%	+28.88%

May. 10	Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 14	Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan	Mar. 07	CI
Alar Pharmaceuticals Inc. Approves Dividend Distribution for the Year Ended December 31, 2023	Mar. 06	CI
Gilva Therapeutics, INC. announced that it expects to receive TWD 30 million in funding from Alar Pharmaceuticals Inc.	Mar. 04	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from United States Patent and Trademark Office	Feb. 22	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Japan Patent Office	Feb. 22	CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Instituto Mexicano De La Propiedad Industrial	Feb. 19	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals	23-10-11	CI
Alar Pharmaceuticals Inc.(TPEX:6785) added to S&P Global BMI Index	23-09-18	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-03	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-11	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
Alar Pharmaceuticals Inc. Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000	22-01-12	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-13	CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-25	CI
Alar Presents Positive Interim Results of Long-Acting Buprenorphine Injectable in Opioid Dependent Patients	21-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alar Pharmaceuticals Inc.

Equities

6785

TW0006785009

Summary

Filters